Science podcast: cracking the Alzheimer’s code

The Swiss Connection science podcast SWI swissinfo.ch

Alzheimer’s has baffled researchers for decades. Drugmakers have poured billions into researching the disease but very few treatments have come on the market. This changed in July 2023 with the approval of lecanemab (Leqembi) in the US. But the drug's path to patients hasn't been smooth sailing, especially in Europe.

Subscribe

Subscribe to

Close

• Apple PodcastsExternal link
• SpotifyExternal link
• Amazon MusicExternal link
• Podcast IndexExternal link
• OvercastExternal link
• YouTubeExternal link
• iHeartRadioExternal link
• PandoraExternal link
• Podcast AddictExternal link
• CastroExternal link
• CastboxExternal link
• PodchaserExternal link
• Pocket CastsExternal link
• DeezerExternal link
• Listen NotesExternal link
• Player FMExternal link
• GoodpodsExternal link
• True FansExternal link
• Buzzsprout RSS Feed External link Copy RSS Feed link Copied Failed to copy

In this episode of ‘The Swiss Connection’External link science podcast we talk about the hope and hype surrounding the latest Alzheimer’s drugs.

The last two years have been an exciting time to be in Alzheimer’s research. Two drugs were approved by US regulators. Lecanemab, sold as Leqembi – made by US firm Biogen and Japanese firm Eisai – and donanemab, sold by Eli Lilly as Kisunla.

Experts have hailed these drugs as breakthroughs but the decision around whether to approve them and pay for them hasn’t been straightforward especially in Europe.

Join pharma and healthcare reporter Jessica Davis Plüss on the ‘The Swiss Connection’External link, where she speaks with experts about why Alzheimer’s disease has been so difficult to crack.

Find out more about the ‘The Swiss Connection’ science podcast and our other Swiss podcasts in English here, on Apple PodcastsExternal link, or SpotifyExternal link.